760-761 / 2437
Socinski et al. J Clin Oncol 2009
De Braganca et al. J Neurooncol 2010
Lévy et al. Ann Oncol 2014
• Only low risk for CNS hemorrhage in patients with NSCLC
and brain mets who are treated with bevacizumab
• Potentially strong anti-edema activity
• Bevacizumab alone or in combination with chemotherapy
in patients with brain mets from NSCLC:
• Median PFS: 7.8 months
• Median OS: 14.1 months
• WBRT + bevacizumab in patients with brain mets
(REBECA):
• Safe, but clinical benefit remains unclear
Bevacizumab